July 25, 2012, Vol 308, No. 4, Pages 315-419 | HIV/AIDS

Paton and coauthors examined CD8 cell activation in 83 patients with asymptomatic HIV infection who were not taking antiretroviral therapy in a randomized, double-blind, placebo-controlled trial of hydroxychloroquine. In an ⁸⁴⁸⁸, Stein and Hsue discuss interventions that target inflammation and immune activation in patients with HIV.

To determine risk of cervical precancer and cancer among human immunodeficiency virus (HIV)-infected women with normal cervical cytology and no evidence of oncogenic human papillomavirus infection, Keller and coauthors followed up 699 women with and without HIV infection enrolled in the Women’s Interagency HIV study.

In a prospective cohort of 638 patients coinfected with human immunodeficiency virus and hepatitis C virus, Limketkai and coauthors investigated the incidence of end-stage liver disease, hepatocellular carcinoma, and death based on baseline hepatic fibrosis and antiviral treatment.